Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.

Hilberdink’s arrival comes at a pivotal time for the company, as Boehringer grows its existing portfolio and accelerates its preparation for the launch of several new assets in its pipeline. He will play a pivotal role in fostering Boehringer’s culture and driving meaningful impact for patients.

Experience

Hilberdink is an accomplished global leader with over 25 years of experience in the pharmaceutical industry, with a strong focus on driving impact and performance and cultivating an engaged and accountable culture. In his previous roles in global marketing, general management and as a commercial leader in the U.S., he had the opportunity to lead several product launches, including multiple blockbusters and rare disease biologics.

Hilberdink most recently served as Executive Vice President at LEO Pharma, where he acted as head of the North American Region and President of the U.S. affiliate, which became the primary growth driver for the company globally. Prior to his tenure at LEO Pharma, Hilberdink held several senior-level positions at Novo Nordisk, where he was recognized for his innovative go-to-market strategies. During his tenure at Novo Nordisk, Hilberdink successfully launched multiple blockbuster products in the fields of obesity and diabetes.

“I’m elated to be joining Boehringer as the company embarks on an exciting new chapter of growth and innovation,” Hilberdink said. “Together, we can continue Boehringer’s legacy of transforming lives for generations and making a positive impact on patients now and in the future.”